The optimal management of T1 high-grade bladder cancer

Journal of the Canadian Urological Association

Volumn 3, Issue 6 SUPPL. 4, 2009, Pages

  Nepple, Kenneth G ^a   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75849151445     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
2. Heney NM, Ahmed S, Flanagan MJ, et al. IR. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
3. Jakse G, Loidl W, Seeber G, et al. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 1987;137:39-43.
4. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982;127:250-2.
5. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6Pt1):2186-90.
6. Cai T, Nesi G, Tinacci G, et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008;180:110-5.
7. Sylvester RJ, Oosterlinck W, O'Donnell. Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci, et al. J Urol 2008;180:110-5. J Urol 2009;181:410.
8. Witjes JA, Kiemeney LA, Schaafsma HE, et al. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. Br J Urol 1994;73:172-6.
9. Millan-Rodriguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164(3Pt1):680-4.
10. Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press;
11. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165:808-10.
12. Orsola A, Trias I, Raventós CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-nontreated patients. Eur Urol 2005;48:231-8.
13. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000;85:48-53.
14. Abel PD, Henderson D, Bennett MK, et al. Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol 1988;62:339-42.
15. Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316-8.
16. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74-6.
17. Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002;60:822-4.
18. Divrik RT, Yildirim U, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641-4.
19. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005;174:2134-7.
20. Hara T, Takahashi M, Gondo T, et al. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. Int J Urol 2009;16:293-8.
21. Gupta A, Lotan Y, Bastian PJ, et al. Bladder Cancer Research Consortium. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008;71:302-7.
22. Kulkarni GS, Finelli A, Fleshner NE, et al. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 2007;4:e284.
23. Kaubisch S, Lum BL, Reese J, et al. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991;146:28-31.
24. Esrig D, Freeman JA, Stein JP, et al. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 1997;15:154-60.
25. Stöckle M, Alken P, Engelmann U, et al. Radical cystectomy-often too late? Eur Urol 1987;13:361-7.
26. Amling CL, Thrasher JB, Frazier HA, et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994;151:31-6.
27. Skinner EC. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 2007;25:523-5.
28. Stein JP, Penson DF. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 2008;102:270-5.
29. Thalmann GN, Markwalder R, Shahin O, et al. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004;172:70-5.
30. Denzinger S, Otto W, Fritsche HM, et al. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol 2007;14:995-9.
31. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
32. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9.
33. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
34. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429-34.
35. Di Stasi SM, Giannantoni A, Giurioli A, et al.Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43-51.
36. Guy L, Savareux L, Molinié V, et al. Should bladder biopsies be performed routinely after bacillus Calmette-Guerin treatment for high-risk superficial transitional cell cancer of the bladder? Eur Urol 2006;50:516-20.
37. Lotan Y, Bensalah K, Ruddell T, et al. Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. J Urol 2008;179:2164-9.
38. Nepple KG, Aubert HA, Braasch MR, et al. Combination of BCG and interferon intravesical immunotherapy: an update. World J Urol 2009;27:343-6.
39. Nadler RB, Catalona WJ, Hudson MA, et al. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 1994;152(2Pt1):367-73.
40. O'Donnell MA, Bohle A. Treatment options for BCG failures. World J Urol 2006;24:481-7.
41. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344-8.
42. Addeo R, Caraglia M, Bellini S, et al. Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. J Clin Oncol; 2009 Oct 19 [Epub ahead of print].
43. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term Clinical Outcomes of a Phase I Trial of Intravesical Docetaxel in the Management of Non-Muscle-Invasive Bladder Cancer Refractory to Standard Intravesical Therapy. Urology 2009; Nov 12 [Epub ahead of print].
44. Quilty PM, Duncan W. Treatment of superficial (T1) tumours of the bladder by radical radiotherapy. Br J Urol 1986;58:147-52.
45. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-8.
46. Inoue M, Ishioka J, Fukuda H, et al. Clinical outcome of chemoradiotherapy for T1G3 bladder cancer. Int J Urol 2008;15:747-50.
47. Weiss C, Wolze C, Engehausen DG, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006;24:2318-24.
48. Hurle R, Losa A, Manzetti A, et al. Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999;54:258-63.
49. Pfister C, Landé P, Hervé JM, et al. T1 G3 bladder tumors: the respective role of BCG and cystectomy. Prog Urol 1995;5:231-7.
50. Mack D, Frick J. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology 1995;45:958-61.
51. Pansadoro V, Emiliozzi P, Defidio L, et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 1995;154:2054-8.
52. Pansadoro V, Emiliozzi P, de Paula F, et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002;59:227-31.
53. Hurle R, Losa A, Ranieri A, et al. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol 1996;156:1602-5.
54. Lebret T, Gaudez F, Hervé JM, et al. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 1998;34:67-72.
55. Gohji K, Nomi M, Okamoto M, et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999;53:308-13.
56. Brake M, Loertzer H, Horsch R, et al. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000;163:1697-701.
57. Patard J, Moudouni S, Saint F, et al. And the members of the Groupe Necker. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001;58:551-6.
58. Kulkarni JN, Gupta R. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain). BJU Int 2002;90:554-7.
59. Griffiths TR, Charlton M, Neal DE, et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002;167:2408-12.
60. Bogdanovi J, Marusi G, Djozi J, et al. The management of T1G3 bladder cancer. Urol Int 2002;69:263-5.
61. Peyromaure M, Guerin F, Amsellem-Ouazana D, et al. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 2003;169:2110-2.
62. Shahin O, Thalmann GN, Rentsch C, et al. A retrospective analysis of 153 patients treated with or with-out intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169:96-100.
63. Cheng CW, Chan SF, Chan LW, et al. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach. Jpn J Clin Oncol 2004;34:202-5.